IBRX vs NKTR
IBRX: ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to harness the immune system against cancer and infectious diseases. NKTR: A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | IBRX | NKTR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.51 | $69.32 | |
| Market cap as of 2026-07-23 | $8.0B | $2.4B | |
| PEG as of 2026-07-23 | -0.21 | n/a | |
| Net margin as of 2026-07-23 | -606.1% | -280.8% | NKTR higher |
| Gross margin as of 2026-07-23 | +99.3% | +100.0% | NKTR higher |
| Operating margin as of 2026-07-23 | -185.4% | -242.0% | IBRX higher |
| ROE as of 2026-07-23 | -193.3% | -45.8% | NKTR higher |
| ROA as of 2026-07-23 | -165.2% | -40.3% | NKTR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.10 | IBRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +351.5% | -36.2% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | +678.6% | -15.7% | IBRX higher |
| Beta as of 2026-07-23 | 0.15 | 1.13 | |
| 1-year return as of 2026-07-22 close | +177.1% | +183.2% | NKTR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.